DGAP-News: ALK: GRAZAX(r) long-term trial highlighted as editor–s choice in leading scientific journal
ALK-Abelló02.03.2012 12:14
—————————————————————————
Summary: Landmark results showing the long-term disease modifying effect of
GRAZAX(r) are published in the American Journal of Allergy and Clinical
Immunology and highlighted as the editor–s choice. The trial is the only
published large double-blind placebo-controlled trial to demonstrate that grass
allergy immunotherapy tablets (AIT) is an efficacious treatment for grass
pollen
